EP 0724577 A1 19960807 - HETEROCYCLIC AMINES FOR TREATING ISCHAEMIC STROKES
Title (en)
HETEROCYCLIC AMINES FOR TREATING ISCHAEMIC STROKES
Title (de)
HETEROCYCLISCHE AMINE ZUR BEHANDLUNG ISCHAEMIC HERZANFÄLLE
Title (fr)
AMINES HETEROCYCLIQUES POUR LE TRAITEMENT DES ACCES ISCHEMIQUES
Publication
Application
Priority
- EP 9403425 W 19941018
- GB 9321811 A 19931022
Abstract (en)
[origin: WO9511238A1] Use of compounds of formula (I), wherein R<1> and R<2> each independently represent: hydrogen, C1-8alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R<3>R<4>NC2-6alkyl (where R<3> and R<4> independently represent H or C1-4alkyl) or NR<1>R<2> represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR<5> (where R<5> is H, C1-4alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S, or C=O; n is 5 to 11; and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy, e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk<1>)pA(Alk<2>)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk<1> and Alk<2> independently represent C1-4alkyl which may be straight or branched and p and q are independently 0 or 1 provided that the length of -(Alk<1>)pA(Alk<2>)q- does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group (a), in which Y<1> is Y<2>(CH2)r where r is 0 or 1 and Y<2> is O, S or NR<6> where R<6> is hydrogen or C1-4alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; with the provisos that (i) when X is O or S, and NR<1>R<2> represents a heterocyclic ring which does not contain an optional further heteroatom then Ar is phenyl substituted by a group Ph(Alk<1>)pC(O)(Alk<2>)q-; (ii) when n is 5 and one of R<1> and R<2> is hydrogen, C1-4alkyl or arylC1-4alkyl, then the other of R<1> and R<2> is not R<3>R<4>NC2-6alkyl; and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for the treatment of a condition where a calcium antagonist is required. Certain novel compounds of formula (I) and processes for preparing them are also described.
IPC 1-7
C07D 295/088; A61K 31/435; C07C 217/54; A61K 31/495; A61K 31/525
IPC 8 full level
A61K 31/135 (2006.01); A61K 31/445 (2006.01); A61K 31/495 (2006.01); A61K 31/535 (2006.01); A61K 31/5375 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01); A61P 25/28 (2006.01); C07C 43/225 (2006.01); C07C 43/295 (2006.01); C07C 217/20 (2006.01); C07D 295/08 (2006.01); C07D 295/092 (2006.01); C07D 295/108 (2006.01)
CPC (source: EP)
A61K 31/135 (2013.01); A61K 31/445 (2013.01); A61K 31/495 (2013.01); A61K 31/535 (2013.01); A61P 9/08 (2017.12); A61P 9/10 (2017.12); A61P 25/04 (2017.12); A61P 25/06 (2017.12); A61P 25/28 (2017.12); C07C 217/20 (2013.01); C07D 295/088 (2013.01); C07D 295/108 (2013.01); C07C 2601/08 (2017.04)
Citation (search report)
See references of WO 9511238A1
Designated contracting state (EPC)
BE CH DE FR GB IT LI NL
DOCDB simple family (publication)
WO 9511238 A1 19950427; AU 7856694 A 19950508; EP 0724577 A1 19960807; GB 9321811 D0 19931215; JP H09504016 A 19970422; ZA 948233 B 19950725
DOCDB simple family (application)
EP 9403425 W 19941018; AU 7856694 A 19941018; EP 94929558 A 19941018; GB 9321811 A 19931022; JP 51132195 A 19941018; ZA 948233 A 19941020